



BIOMM SA
Public Company
CNPJ/MF No. 04.752.991/0001-10
NIRE No. 31.300.016.510

MATERIAL FACT

BIOMM SA ("Company" or "Biommm"), in compliance with the provisions of Resolution of the Brazilian Securities Commission No. 44, of August 23, 2021, hereby informs its shareholders and the market in general that, on the date hereof, it entered into an exclusive agreement with Bioeq AG, a swiss biosimilar company ("Bioeq") for the registration and distribution of a biosimilar **ranibizumab** (BQ201) in Brazil.

Ranibizumab is a monoclonal antibody fragment indicated for the treatment of severe and debilitating retinal diseases such as treatment Age-Related Neovascular (wet) Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Macular Edema following Retinal Vein Occlusion (RVO) and Myopic Choroidal Neovascularization (mCNV). The drug acts by inhibiting angiogenesis (the natural process of formation of new blood vessels) by binding to and blocking the Vascular Endothelial Growth Factor (VEGF) otherwise promoting excessive blood vessel formation.

The ranibizumab biosmililar BQ201 has been developed by Bioeq, a biopharmaceutical joint venture between Formycon AG and Polpharma Biologics Group registered in Zug, Switzerland. Bioeq develops, licenses and commercializes biosimilars globally in compliance with the quality standards of highly regulated markets such as the United States (USA) and European Union (EU).

With the expansion of its biologics portfolio with this first ophthalmologic sterile injectible biosimilar, Biommm reinforces its commitment to improving access to high-quality biological treatments of serious diseases for the Brazilian population and to further contribute to the efficiency, sustainability and quality of its health care system.

Biommm will keep its shareholders and the market informed about the subject matter of this material fact.

Nova Lima/MG, October 04, 2022.

Mirna Santiago Vieira
Chief Financial and Investor Relations Officer